Abstract:Although TP53 co-mutation with KRAS have been proved to have predictive value for response to PD-1/L1 blockades, not all TP53 mutations are equal in this context. TP53 subtypes as independent factors to predict the response to PD-1/L1 blockade have not yet reported. We performed an integrated analysis on the multiple-dimensional data types including genomic and clinical data from cohorts of NSCLC public (240 from MSK database) and local databases (224 patient with PD-L1 IHC score, 1986 NSCLC with TMB data). Durable clinical beneﬁt (DCB) was deﬁned as partial response/stable disease that lasted more than 6 months. The presence of mutant TP53 was associated with longer median progression free survival (mPFS) in NSCLC taking PD-1/L1 blockade therapy compared with TP53 wild-type group in the MSK-cohort (4.3 vs2.6 months, P=0.0027, HR=0.6409, 95%CI, 0.49 to 0.88). TP53 frameshift seemed to predict longer mPFS (6.6 months, P=0.0159, HR= 0.41, 95%CI, 0.26 to 0.65) than TP53 wild-type, TP53 missense (mPFS=4.27 months, P=0.17) and TP53 nonsense status (mPFS=2.7 months, P=0.002).NSCLC with TP53 frameshift mutation had a 52.9% rate of DCB, which was higher than TP53 missense (34.4%) and nonsense (21.1%) group. Besides, in the MSK cohort, five of six patients with TP53 truncated mutation in proline-rich (PR) domain (residues 58--101) achieved DCB, and one patient achieved 5.5 months of PFS and did not progress. Fractions of PD-L1 low-positive (1% - 49%) and PD-L1 high-positive (≥50%) tumors between each TP53 mutation subtype and wild-type groups are analyzed based on local data. The TP53 mutation rate was significantly higher in NSCLC with PD-L1 score >50% (P=0.004). But NSCLC with TP53 frameshift showed lower fractions of PD-L1 high-positive (12.5%, 2/16) compared with TP53 missense group (27.5%, 33/120) and TP53 nonsense group (25.8%, 8/31). PD-L1 low-positive rate is also lower in TP53 frameshift group (25.0%, 4/16) than TP53 missense (30.8%, 37/120) and nonsense group (29.0%, 9/31). Among 1986 NSCLC patients with TMB data, each TP53 mutation subtype is associated with significantly higher TMB than TP53 wildtype, especially among NSCLC with TP53 truncated mutation in PR domain (median TMB= 9 mut/Mbs). But no significant difference was found between TP53 mutation subtypes in TMB. Our study demonstrated heterogeneity among TP53 mutations in predicting the response to PD-1/L1 blockade therapy. TP53 frameshift mutation may contribute to better PD-1/L1 blockade therapy response beyond PD-1/L1 IHC status. And the truncated TP53 mutation in PR domain may contribute to DCB.

MEDU-05. PROGNOSTIC IMPLICATION OF TERT PROMOTER MUTATION AND TP53 NUCLEAR STAINING IN ADULT MEDULLOBLASTOMA

PATH-32. CLINICAL AND MUTATIONAL PROFILES OF ADULT MEDULLOBLASTOMA GROUPS

Molecular Subgroups of Adult Medulloblastoma: a Long-Term Single-Institution Study.

A Retrospective Study of Progression-Free and Overall Survival in Pediatric Medulloblastoma Based on Molecular Subgroup Classification: A Single-Institution Experience.

Prognostic value of Ki-67 index in adult medulloblastoma after accounting for molecular subgroup: a retrospective clinical and molecular analysis

Comprehensive Profiling of MDM2/TP53 Genomic Aberration in Chinese Patients with Diverse Malignancies.

Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy

MEDB-05. Survival and prognostic factors in childhood medulloblastoma: A China single center experience from 2006 to 2015

Distinctive Localization and MRI Features Correlate of Molecular Subgroups in Adult Medulloblastoma

Clinical Characterization of Adult Medulloblastoma and the Effect of First-Line Therapies on Outcome; the MD Anderson Cancer Center Experience

PATH-34. H3F3A AND TERT PROMOTER MUTATIONS ARE POOR PROGNOSTICATORS IN PEDIATRIC LOW-GRADE GLIOMAS

RARE-47. CHARACTERIZATION OF ADULT MEDULLOBLASTOMA; A RETROSPECTIVE REVIEW OF 200 PATIENTS AT MD ANDERSON CANCER CENTER

Medulloblastoma: Molecular understanding, treatment evolution, and new developments

Clinical Outcomes of Adult Medulloblastoma: A Retrospective Analysis at a Single Institute

JCSE01.23 Specific TP53 Mutation Subtypes As Biomarker for Response to PD-1/L1 Blockade Immunotherapy in NSCLC

PDTB-08. Mir-449a, A POTENTIAL DIAGNOSTIC BIOMARKER FOR WNT GROUP OF MEDULLOBLASTOMA

Single‐Cell Chromatin Accessibility Analysis Reveals Subgroup‐Specific TF‐NTR Regulatory Circuits in Medulloblastoma

Prognostic significance of molecular subgroups in survival outcome for children with medulloblastoma in Malaysia

Subgroup-Specific Diagnostic, Prognostic, and Predictive Markers Influencing Pediatric Medulloblastoma Treatment

Differences in the Prognostic Value of Tumor Extent of Resection among the Molecular Subgroups of Medulloblastoma: A Single Centre Study of 113 Cases

Clinical Characteristics And Prognostic Significance Of Tert Promoter Mutations In Cancer: A Cohort Study And A Meta-Analysis